Skip to main content

Mechanisms of PhotoBioModulation (PBM) focused on oral mucositis prevention and treatment: a scoping review

Abstract

Background

Oral mucositis (OM) is a severe complication cancer patients undergo when treated with chemoradiotherapy. Photobiomodulation (PBM) therapy also known as low-level laser therapy has been increasingly used for the treatment of such oral toxicity. The aim of this review is to discuss the mechanisms of photobiomodulation (PBM) regarding OM prevention and treatment, and more precisely to focus on the effect of PBM on tumor and healthy cells.

Methods

MEDLINE/PubMed, and google scholar were searched electronically. Selected studies were focusing on PBM effects on tumor and healthy cells.

Results

PBM interactions with the tissue and additional mechanism in OM therapy were detailed in this review. Moreover, this review highlighted a controversy about the carcinogenic effect of PBM. Indeed, Many studies reported that PBM could enhance malignant cell proliferation; suggesting that PBM would have no protective effect. In addition to acting on cancer cells, PBM may damage healthy cells.

Conclusion

More prospective studies are needed to assess the effect of PBM on cancer cells in order to improve its use for OM prevention and treatment.

Peer Review reports

Background

Almost all patients undergoing Radiation Therapy (RT) and chemoradiotherapy suffer from complications and adjacent tissue damage. Acute complications include Oral Mucositis (OM), pain, dysphagia, infections, salivary changes, dysgeusia, and dermatitis. All these oral toxicities can potentially lead to treatment interruption, dose-limiting toxicity, and eventually a lower quality of life for the patient.

Mucositis is the inflammation and ulceration of the superficial membrane overlying the digestive tract. It results from the disruption of rapidly dividing epithelial progenitor cells. OM appears when the inflammation of the mucous involves the mouth and oral oropharyngeal segment. Inflammation is mostly induced by the formation of excessive Reactive Oxygen Species (ROS) and activation of nuclear factor kappa B (NF-κB). In healthy oral mucosa, complete replacement of the epithelial cell layer is around 4 to 8 days whereas in sick OM, it takes about 20 days to initialize and heal. Such complication has a significant impact on patient’s quality of life, treatment outcomes as well as health care cost. Indeed, severe OM may result in hospitalization, narcotic analgesic use, total parental nutrition [1]. OM prevalence was at 22.3% in patients with advanced cancer [1]: 40% of those who received chemotherapy and 100% of those treated by radiotherapy developed OM [2]. Thus, it seems necessary to focus on solutions that can prevent, relieve or treat this oral toxicity.

Phototherapy involves the application of low-level or low-powered light sources on sites of injury to speed up cellular regeneration processes. Patients are exposed to a given wavelength for some time. It is currently used to speed up healing and reduce inflammation and pain. This non-invasive and non-thermal treatment enables to modulate a wide variety of biological processes. It involves photon energy absorption by the cell, which results in a photochemical effect.

For the biological processes to happen, cells must receive a biphasic dose (optimal dose of light for any particular application). A biphasic dose response has frequently been observed where low levels of light have a much better effect on stimulating and repairing tissues than higher levels of light. Thus, phototherapy can be used for wound healing, tissue repair and prevention of tissue death. Moreover, it can relieve inflammation in chronic diseases and injuries; and of neurogenic pain and some neurological problems.

The aim of this review is to discuss the mechanisms of PhotoBioModulation (PBM) regarding oral mucositis prevention and treatment, and more precisely to focus on the effect of PBM on tumor and healthy cells.

Methods

A literature search for relevant scientific studies indexed between 2000 and 2019 were conducted. The aim of this review is to evaluate the effect of PBM on tumor and healthy cells. Search strategy:

Medline/Pubmed and google scholar were screened. The request formulated in MEDLINE was built in the following way. (((low level laser therapy [MeSH Terms]) OR (laser therapy [MeSH Terms])) OR (photobiomodulation[Other Term])) AND (oral mucositis[MeSH Terms]). The same process was carried out in google scholar data base. Articles were selected based on defined inclusion and exclusion criteria.

Inclusion and exclusion criteria

According to clinical practice guidelines recommendation for mucositis, only the results on cancer cells using PBM wavelengths between 630 and 670 nm were retained. Relevant prospective, retrospective, thesis, experimental studies were included. Review, systematic reviews, case reports, metaanalysis letters to editors, editorials were excluded.

Study selection

The titles of 233 (MEDLINE) and 1050 (google scholar) articles were then verified. The duplicates were also excluded. Then manual researches were carried out by reading all full text of the included references. The studies were then classified into two categories: the effect of PBM on either healthy cells or tumors cells. The main results were then tabulated depending on the effect of PBM on cells and on the type of experimentations (in vitro, in vivo).

Results

Mechanism of action of photobiomodulation

Photobiomodulation (PBM) also known as Low Level Laser Light therapy (LLLT) is a phototherapy that employs low-level power light to specifically relieve pain and heal wounds.

PBM relies on the effect of light on biological systems. It is maximized when both light penetration is the deepest, and photoacceptors absorption is the highest. In mammalian tissues, the main chromophores that absorb light in this Near-infrared spectroscopy (NIR) range are hemoglobin, myoglobin, melanin, and mitochondrial Cytochrome c Oxydase (Cco) [3]. Light penetration in tissues is maximal for an optical window where the absorption by all major compounds of the body is minimum. The optimum wave length is between 650 and 950 nm [4].

The literature reported four possible mechanisms for PBM cellular actions. Indeed, several pieces of evidence suggested that PBM stimulated mitochondrial activity and enhanced various cellular processes of the respiratory chain. Cco, a chromophore located in mitochondria, absorbed light energy, therefore reaching an excited state where its redox status was altered. Since infrared photons were absorbed by electronic absorption bands belonging to Cco resulting in an emission of electrons, Cco oxidation state is increased.

It was first hypothesized that the light absorption by Cco causes an increase in the rate of the electron transfer of the respiratory chain, thus, increasing the rate of ATP production [4]. ATP is energy, an essential ingredient for all biologic reactions. Even a small increase can enhance bioavailability to power the functions of cellular metabolism.

Secondly, it was hypothesized that Cco could have two enzymatic activities, the conversion of NO2- into NO and the reduction of O2 into H2O. In literature, PBM in NO’s activity had antagonist effects [5]. On the one hand, as the activity of Cco increased and so did the production of NO is [6]. This was a negative effect as NO could inhibit respiration by binding to Cco instead of binding to O2. It provoked a lower electron transfer rate in the respiratory chain, thus a lower amount of ATP produced [4]. On the other hand, PBM might generate NO and Cco dissociation; thus providing the body with free NO [4]. It is a positive effect enhanced by light.

Overall, PBM enhanced an increase in NO production that binded to Cco; but also dissociated Cco and NO. As a result, more free NO was liberated. The free NO could enhance downstream effects such as systemic blood pressure, hypoxic signalling, stress response pathways, host-microbe interactions, immune signalling, and apoptosis. The stimulatory effect of light on NO is given by a wavelength excitation in between 509 and 691 nm whereas the inhibitory effect is predominant for a wave length of about 820 nm [6]. When focused on wound healing, NO could stimulate vasodilatation and indirectly regulate transcription over many mammalian genes [6].

Thirdly, it was hypothesized that PBM could have antagonist effects on ROS formation. At first, it generates a shift in the Red/Ox potential of the cells through greater oxidation [4]. Thereby, it causes an oxidative stress where the production of ROS and the ability of a biological system to detoxify them is unbalanced. This action is short and followed by an adaptive reduction in oxidative stress by mimicking the activity of molecular agents that attenuate tissue damage [7].

Such anti-oxidant effect is greater in hypotoxic, stressed or damaged cells than in normal cells, because these cells are more likely to respond and reduce O2 concentrations. ROS displayed an important role in cell signalling pathways from mitochondria to nucleus, regulating cell cycle progression, protein synthesis, and nucleic acid synthesis and enzyme activation. So, ROS played a key role in homeostasis and cell signalling. However, even at low concentrations, ROS could damage cell components by lipid peroxidation, DNA strand break and protein fragmentation [8].

Finally, it was hypothesized that as part of the energy is converted into heat, a photothermal effect is generated and spread along tissues. This hypothesis lacks proofs as, so far, little has been known about photoacceptor molecules [8].

The downstream intracellular responses are driven by photosignal transduction and amplification in response mostly to ATP, ROS and NO concentration change. These effects are seen inside the cell. Indeed, ATP provides the energy needed by the cell and drives many biochemical processes such as protein synthesis. It is currently explained in the literature that ATP activates cAMP and is linked to Ca2+ pump activity. These assumptions remain uncertain [9]. cAMP and Ca2+ are two major second messengers of the body. Ca2+ regulates most human body processes such as muscle contraction, blood coagulation, signal transfer in nerves, gene expression [10].

AP-1 is the main signalling pathway generated after ATP increase. Simultaneously, when the number of ROS increases, cells emit signals to recuit anti-oxidative molecules. The activation of these signalling pathway results in transcription factors upregulating genes. NF-κB is the main signalling pathway due to oxidative stress [8]. NF-κB and AP-1 induces cell proliferation, growth factor production, anti-apoptotic, and antioxidant effects. Moreover, the activation of pro-adhesion molecule synthesis, leads to leukocytes migration into inflammatory sites. And so confers an adaptive immunity to fight against pathogens present in wound healing. Furthermore, pro-inflammatory agents such as cytokines and chemokine production are also activated. Two cytokines could be highlighted for their major role in wound healing. IL-6 plays a central role in the response to injuries, with both pro and anti-inflammatory effects. It stimulates the proliferation of fibroblasts that synthesize many components of the structural framework of tissues. IL-10 is an anti-inflammatory cytokine that inhibits the production of pro-inflammatory cytokines as well as the infiltration of macrophages and neutrophils [11]. Growth factors such as bFGF, HGF and SCF contribute to pre-regulate the cytokines responsible for fibroblast proliferation and migration. In addition, vascular endothelial growth factors (VEGF) is responsible for neovascularization useful for wound healing. Lastly, TGF-alpha growth factor induces collagen synthesis from fibroblasts to undergo the transformation into myofibloblasts, a cell type that expresses smooth.

At the tissue level, PBM for OM is used in order to accelerate and ensure each phase of the wound healing process. Indeed, first PBM had an effect on pathogens elimination, and neovascularization stimulation. Therefore, it facilitates the migration of immune cells to the infection site [12]. Secondly, ROS plays a role in platelet activation. A quick increase in ROS and NO production generates signalling pathways leading to recruitment and production of inflammatory markers [8]. After a short raise in ROS production, inflammation is reduced by the release of anti-inflammatory markers and decrease in inflammatory mediators and neutrophil infiltration.

Moreover, an increase in ATP production and NO signalling induces cell migration, proliferation, inhibition of apoptosis and angiogenesis (formation of new blood vessels) [13]. Lastly, collagen production is achieved by transformation of fibroblasts to myofibroblasts. LLLT could contribute to collagen fibers alignment which enhances epidermal and scar tissue formation [12].

In short, PBM in near infra-red can lead to a reduction in inflammation through inflammatory markers and vascularisation. Moreover, it has an effect on cytoprotection effect. Studies have shown that in vitro PBM protects cells at risk of dying due to treatment with toxins. Finally, it enhances proliferation and cells migration (cells regulating pro-survival, anti-apoptotic proteins, collagen synthesis). It leads to hastened wound healing and decrease pain, swelling and inflammation [8].

Cytotoxic effects of PBM

A-Effects of PBM on cancer cells

The effect of PBM on cancer cells is a controversial issue in the literature. Many studies found that PBM could enhance malignant cell proliferation; and biostimulation, suggesting that PBM had no protection effects. PBM could also efficiently activates a sweeping range of pathways and mediators which involved in tumor conduct [7]. Some cancerous cells, such as the ones at the border of a malignant tumor, are enriched with small amounts of photosensitizers and may proliferate better after irradiation [14, 15]. Indeed, Sperandio et al. showed that LLLT significantly modified the expression of proteins related to progression and invasion and could aggravate oral cancer cell behaviour [16]. Similarly, LLLT had a stimulatory effect on proliferation and invasion of SCC-25 cells [17]. Likewise, LLLT induced a significant increase in the percentage of S-phase associated with a decrease in SCC-25 cells proliferation [18].

In vivo experiment with anaplastic thyroid cancer cell line injected into nude mice showed an over proliferation and angiogenesis of the anaplastic thyroid carcinoma [19]. However, other studies revealed no negative effects on cancer cells as it could promote immunological response to cell deficiency. Indeed, high-fluence, low-power laser irradiation induced cancer cell apoptosis and antitumor immune response via photoinactivation of respiratory chain oxidase [20]. Likewise, Silva et al. study showed an increase in the number of senescent cells in response to LLLT [21]. All the results are detailed in Table 1.

Table 1 Effect of PBM on cancer cells, in vitro and in vivo experiments between 630 and 670 nm

Potential negative effects of PBM on healthy cells

In addition to its effects on cancer cells, PBM may damage on healthy cells.

DNA damage

Even if PBM has been proved to induce healthy cell proliferation; it seems relevant to study whether it could cause healthy cells damage or not. Schartinger et al., showed differential response of fibroblast, non-neoplastic epithelial cells to LLLT. Indeed, these cell lines were subjected to LLLT (660 nm, 350mW) on three consecutive days for 15 min. LLLT treatment resulted in increased human gingival fibroblast proliferation, whereas decreased cell proliferation was observed in non-malignant epithelial cells [18]. Khan et al. evaluates whether ROS generation by laser treatments led to direct DNA damage that could result in genotoxicity and potential mutagenicity.The same authors indicate that NIR laser can be phototoxic without being genotoxic or mutagenic [22].

Cytotoxicity induced by ROS and NO

PBM could have cytotoxic effects because of ROS and NO production. Even at low concentrations rates, ROS could damage cell components through lipid peroxidation, DNA strand break and protein fragmentation [8].

Khan et al. demonstrated that in vitro laser treatments with increasing doses in clear plastic wells failed to induce significant phototoxicity. However, laser phototoxicity was clearly visible at doses over 27 J/cm2. Furthermore, phototoxicity was mediated by heat and ROS. When cells are heat, ROS scavengers (ROS support) that act along with dose-dependent ROS effector generation are inactivated. It results in phototoxic tissue damage [22]. As OncoRed technology allows cells to be away from the heating source, it should not be an issue. The authors of the same study demonstrated that in the case of PBM, the genes leading to phototoxicity were linked to activation of ER stress pathway through ATF-4, a master regulator of cellular stress response [22].

In vitro, in vivo, and trials: the effect of PBM on healthy cells

Information about many random trials and different clinical applications is provided in literature. In vitro experiments resulted in increased fibroblast proliferation, whereas decreased cell proliferation was observed after LLLT exposition in mon-malignant BEAS-2B epithelial cells [18]. Furthermore, in in vitro wound-healing model, LLLT at a wavelength of 650 nm increased cellular migration and proliferation at doses of 0.1, 0.2, and 1.2 J/cm while exposure to 10 J/cm2decreased cellular migration and proliferation [23].

Due to Light-Emitting Diode irradiation, a 140–200% increase in cell growth was reported in mouse-derived fibroblasts, rat-derived osteoblasts, and rat-derived skeletal muscle cells As to normal human epithelial cells they grew by 155 to 171% [24]. All details of these experiments are summarized in Table 2.

Table 2 In vitro studies on the effect of PBM on healthy cells

Only experiments where a wavelength between 630 and 660 nm on stem cells were detailed in this review. A review by Bayat et al. grouped all in vitro experiments using different wavelength LLLT with on stem cells and osteoblasts [25]. LLLT enhanced a significant increase in the initial number of stem cells [25]. Likewise, LLLT could improve the viability and proliferation rate of healthy and osteoporotic bone marrow Mesenchymal Stem Cells (MSC) [26].Interestingly, diode laser is a relevant approach for the preconditioning of MSC prior cell transplantation [28]. LLLT on adipose-derived MSC resulted in rapid bone formation [28]. Furthermore, in response to Low-Level Laser Irradiation (LLLI), miR-193 played a crucial role in MSC proliferation [29]. Moreover, multiple dose of LLLI could enhance the osteogenic potential of rat MSCs [30]. Photomodulation therapy using LED irradiation downregulates osteoclastogenesis [31]

As to in vivo studies, Fekrazad el al. made an electronic database research in PubMed, ISI Web of Knowledge and Google scholar with key words such as “oral mucositis” and “low level light therapy”. They reviewed all the relevant papers from 2000 to 2013, and excluded meta-analysis, reviews and the articles when it was not possible to reach the full text. This review assessed 2 animals and 24 humain studies [13]. All studies provided positive results showing that PBM reduced the severity of mucositis [13] low-energy laser was well-tolerated and showed beneficial effects on the management of OM [32].

Among couple of randomized controlled trials on this subject, Bensadoun et al. conducted a multicenter phase III randomized study in head and neck cancer patients. They used a He–Ne laser daily during five consecutive days, each week during the seven weeks of radiotherapytreatment. Device parameters were a wavelength of 632.8 nm, 2 J/cm2, applied for 33 s or 80 s. The study included 186 patients. When PBM was not used, 35.2% of patients experienced grade 3 mucositis whereas only 7.6% experienced such toxicity when PBM was used.. The frequency of “severe pain” (grade 3) was 23.8% without PBM falling to 1.9% with it [33]

Migliorati et al. made a systematic review of laser and other light therapy in the management of OM in cancer patients [34]. They identified two results about the use of LED at 645 and 670 nm. For their literature search, all papers were assessed according to their relevance and methodological quality. Indeed, a pilot study showed that LED treatment is safe and enable to reduce the duration of chemotherapy-induced mucositis [35].

Discussion

OM is considered as a debilitating complication of radiotherapy or chemotherapy in head and neck cancer patients. Thus, it seems necessary to prevent, relieve or treat this oral toxicity. LLLT or PBM is a part of OM management as it is enables to prevent reduction or discontinuation of treatment [36]. Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC = ISOO) Clinical Practice Guidelines for mucositis recommended a preventive dose of 2 J/cm2 to be applied at a wavelength of 650 nm and a power of 40mW [37].

The number of studies assessing the use of laser therapy in the prevention and treatment of OM is growing, However this review results showed the use of a variety of LLLT and other light devices with different protocols and wavelengths, thus complicating data interpretation. Indeed, PBM parameters have been mostly was performed by diode lasers including red and infra-red wavelength range of 600 to 1000 nm, with a power density between 5 and 150 nW/cm2 for 30 to 60 s per point. Shorter wavelengths (633–700 nm) can reach superficial layer of epithelium. Wavelengths from 780 to 950 nm penetrate deeper affecting sub-epithelial tissues. No particular activity was reported for wavelengths between 700 and 770 nm [7]. Therapeutic effect driven by the energy density is also dependant on non-adjustable parameters such as cell type and redox state. Both laser and LED have similar biological effects. Indeed, these non-pharmacological devices induces MSCs proliferation [26, 30]. It seems that, the only difference between these two devices is light coherence and power.

Most in vivo experiments on healthy cells showed that PBM reduced the severity of mucositis. Regardless of the wavelength and of the administration scheme, the laser or the LED induce an increase in the proliferation of fibroblasts and an increase in the synthesis of collagen (Tables 2, 3). Indeed, laser could increase the production of VEGF resulting in angiogenesis and therefore improved microcirculation and thus to wound healing [38]. Moreover, LLLT induced a reduction in neutrophil infiltrate and cyclooxygenase-2 (COX-2) expression leading to wound healing [38]. In addition to decrease the inflammation, LLLT had analgesics effects. Indeed, pain was significantly relieved in patients with carcinoma of oral cavity and treated with low level helium–neon (He–Ne) laser therapy [39]. However, all these experiments used distinct from different species with different PBM treatment modalities.The 2018 WALT meeting agreed a consensus in relation with the optimum dose in many treatment modalities including OM[43]. 5 J/cm2 at cellular level, with low rate of energy delivery between 10 and 150 m W/cm2 are recommended. Thus further studies using these modalities are required to achieve a high level of acceptance.

Table 3 In vitro experiments on stem cells with light

In vitro and in vivo studies investigating the effects of PBM on the proliferation of cancer cells raised concerns about the oncological safety of the use of PBM in cancer patients [40]. As highlighted in this review these studies obtained controversial results. Barasch et al. concluded that pre-radiation exposure to LLLT treatment resulted in a different response in normal vs malignant cells [41]. Likewise, LLLT increased cell proliferation in a dose-dependent manner in head and neck squamous cell carcinoma cells but not in normal epithelial tonsil cells [42]. All these studies suggested that LLLT should be used with caution when treating oropharyngeal mucositis in HNSCC patients. Yet, some studies demonstrated that PBM induced apoptosis and malignant cell death in dose-dependent manner [41].

Conclusion

In conclusion, this review highlighted controversial results about PBM treatment on malignant and healthy cells. Furthermore, the methodological differences and low number of studies with high level of evidence unviable a conclusion. Further prospective studies are necessary to fully decode the mechanism action of laser therapy and validate its safe as a promising treatment.

Availability of data and materials

Not applicable.

Abbreviations

OM:

Oral mucositis

PBM:

Photobiomodulation

LLLT:

Low-level laser therapy

RT:

Radiation therapy

ROS:

Reactive oxygen species

NF-κB:

Nuclear factor kappa B

NIR:

Near-infrared spectroscopy

Cco:

Cytochrome c oxydase

COX-2:

Cyclooxygenase-2

MSC:

Mesenchymal stem cells

VEGF:

Vascular endothelial growth factors

He-Ne:

Helium-neon

References

  1. 1.

    Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F, et al. Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer. 2015;23:3249–55.

    PubMed  Article  Google Scholar 

  2. 2.

    Bjordal JM, Bensadoun R-J, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19:1069–77.

    PubMed  Article  Google Scholar 

  3. 3.

    Hüttemann M, Kadenbach B, Grossman LI. Mammalian subunit IV isoforms of cytochrome c oxidase. Gene. 2001;267:111–23.

    PubMed  Article  Google Scholar 

  4. 4.

    Huang Y-Y, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy—an update. Dose Response. 2011;9:602–18.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Poyton RO, Ball KA. Therapeutic photobiomodulation: nitric oxide and a novel function of mitochondrial cytochrome c oxidase. Discov Med. 2011;11:154–9.

    PubMed  Google Scholar 

  6. 6.

    Hamblin MR. Chapter 10 molecular basis for photobiomodulation: light-induced nitric oxide synthesis by cytochrome c oxidase in low-level laser therapy. In: Handbook of low-level laser therapy. Pan Stanford Publishing; 2017.

  7. 7.

    Zecha JAEM, Raber-Durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24:2781–92.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Hamblin MR. Chapter 9 role of reactive oxygen species in low-level laser therapy. In: handbook of low-level laser therapy. Pan Stanford Publishing.

  9. 9.

    de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016. https://doi.org/10.1109/JSTQE.2016.2561201.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Farivar S, Malekshahabi T, Shiari R. Biological effects of low level laser therapy. J Lasers Med Sci. 2014;5:58–62.

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Silva GBL, Sacono NT, Othon-Leite AF, Mendonça EF, Arantes AM, Bariani C, et al. Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study. Lasers Med Sci. 2015;30:117–26.

    PubMed  Article  Google Scholar 

  12. 12.

    Hamblin MR. Chapter 16 low-level laser (light) therapy for wound healing in animal models. In: Handbook of low-level laser therapy. Pan Stanford Publishing; 2017.

  13. 13.

    Fekrazad R, Chiniforush N. Oral mucositis prevention and management by therapeutic laser in head and neck cancers. J Lasers Med Sci. 2014;5:1–7.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE. Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 2016;54:7–14.

    PubMed  Article  Google Scholar 

  15. 15.

    Lubart R, Friedmann H. LLLT and PDT. Laser Ther. 2011;20:233.

    PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Sperandio FF, Giudice FS, Corrêa L, Pinto DS, Hamblin MR, de Sousa SCOM. Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway. J Biophotonics. 2013;6:839–47.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Gomes Henriques ÁC, Ginani F, Oliveira RM, Keesen TSL, Galvão Barboza CA, Oliveira Rocha HA, et al. Low-level laser therapy promotes proliferation and invasion of oral squamous cell carcinoma cells. Lasers Med Sci. 2014;29:1385–95.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Schartinger VH, Galvan O, Riechelmann H, Dudás J. Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy. Support Care Cancer. 2012;20:523–9.

    PubMed  Article  Google Scholar 

  19. 19.

    Rhee Y-H, Moon J-H, Choi S-H, Ahn J-C. Low-level laser therapy promoted aggressive proliferation and angiogenesis through decreasing of transforming growth factor-β1 and increasing of Akt/Hypoxia inducible factor-1α in anaplastic thyroid cancer. Photomed Laser Surg. 2016;34:229–35.

    PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Lu C, Zhou F, Wu S, Liu L, Xing D. Phototherapy-Induced Antitumor Immunity: Long-Term Tumor Suppression Effects via Photoinactivation of Respiratory Chain Oxidase-Triggered Superoxide Anion Burst. Antioxid Redox Signal. 2015;24:249–62.

    PubMed  Article  Google Scholar 

  21. 21.

    Ramos Silva C, Cabral FV, Camargo D, Morais CF, Núñez SC, Mateus Yoshimura T, et al. Exploring the effects of low-level laser therapy on fibroblasts and tumor cells following gamma radiation exposure. J Biophotonics. 2016;9:1157–66.

    PubMed  Article  Google Scholar 

  22. 22.

    Khan I, Tang E, Arany P. Molecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stress. Sci Rep. 2015;5:10581.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Gagnon D, Gibson TWG, Singh A, Zur Linden AR, Kazienko JE, LaMarre J. An in vitro method to test the safety and efficacy of low-level laser therapy (LLLT) in the healing of a canine skin model. BMC Vet Res. 2016;12:73.

    PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Whelan HT, Smits RL, Buchman EV, Whelan NT, Turner SG, Margolis DA, et al. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg. 2001;19:305–14.

    PubMed  Article  Google Scholar 

  25. 25.

    Bayat M, Virdi A, Rezaei F, Chien S. Comparison of the in vitro effects of low-level laser therapy and low-intensity pulsed ultrasound therapy on bony cells and stem cells. Prog Biophys Mol Biol. 2018;133:36–48.

    PubMed  Article  Google Scholar 

  26. 26.

    Fallahnezhad S, Piryaei A, Tabeie F, Nazarian H, Darbandi H, Amini A, et al. Low-level laser therapy with helium-neon laser improved viability of osteoporotic bone marrow-derived mesenchymal stem cells from ovariectomy-induced osteoporotic rats. J Biomed Opt. 2016;21:98002.

    PubMed  Article  Google Scholar 

  27. 27.

    Giannelli M, Chellini F, Sassoli C, Francini F, Pini A, Squecco R, et al. Photoactivation of bone marrow mesenchymal stromal cells with diode laser: effects and mechanisms of action. J Cell Physiol. 2013;228:172–81.

    PubMed  Article  Google Scholar 

  28. 28.

    Choi K, Kang B-J, Kim H, Lee S, Bae S, Kweon O-K, et al. Low-level laser therapy promotes the osteogenic potential of adipose-derived mesenchymal stem cells seeded on an acellular dermal matrix. J Biomed Mater Res Part B Appl Biomater. 2013;101:919–28.

    Article  Google Scholar 

  29. 29.

    Wang J, Huang W, Wu Y, Hou J, Nie Y, Gu H, et al. MicroRNA-193 pro-proliferation effects for bone mesenchymal stem cells after low-level laser irradiation treatment through inhibitor of growth family, member 5. Stem Cells Dev. 2012;21:2508–19.

    PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Li W-T, Leu Y-C, Wu J-L. Red-light light-emitting diode irradiation increases the proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells. Photomed Laser Surg. 2010;28(Suppl 1):S157-165.

    PubMed  Article  Google Scholar 

  31. 31.

    Sohn HM, Ko Y, Park M, Kim B, Park JE, Kim D, et al. Comparison of the alendronate and irradiation with a light-emitting diode (LED) on murine osteoclastogenesis. Lasers Med Sci. 2017;32:189–200.

    PubMed  Article  Google Scholar 

  32. 32.

    Sandoval RL, Koga DH, Buloto LS, Suzuki R, Dib LL. Management of chemo- and radiotherapy induced oral mucositis with low-energy laser: initial results of A.C. Camargo Hospital. J Appl Oral Sci. 2003;11:337–41.

    PubMed  Article  Google Scholar 

  33. 33.

    Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer. 1999;7:244–52.

    PubMed  Article  Google Scholar 

  34. 34.

    Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun R-J, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3969–83.

    Article  Google Scholar 

  35. 35.

    Corti L, Chiarion-Sileni V, Aversa S, Ponzoni A, D’Arcais R, Pagnutti S, et al. Treatment of chemotherapy-induced oral mucositis with light-emitting diode. Photomed Laser Surg. 2006;24:207–13.

    PubMed  Article  Google Scholar 

  36. 36.

    Simões A, Eduardo FP, Luiz AC, Campos L, Sá PHRN, Cristófaro M, et al. Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers Surg Med. 2009;41:264–70.

    PubMed  Article  Google Scholar 

  37. 37.

    Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.

    PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Lopes NNF, Plapler H, Chavantes MC, Lalla RV, Yoshimura EM, Alves MTS. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer. 2009;17:1409–15.

    PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Arun Maiya G, Sagar MS, Fernandes D. Effect of low level helium-neon (He-Ne) laser therapy in the prevention & treatment of radiation induced mucositis in head & neck cancer patients. Indian J Med Res. 2006;124:399–402.

    PubMed  Google Scholar 

  40. 40.

    de Pauli PM, Araújo ALD, Arboleda LPA, Palmier NR, Fonsêca JM, Gomes-Silva W, et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities: A systematic review. Oral Oncol. 2019;93:21–8.

    Article  Google Scholar 

  41. 41.

    Barasch A, Raber-Durlacher J, Epstein JB, Carroll J. Effects of pre-radiation exposure to LLLT of normal and malignant cells. Support Care Cancer. 2016;24:2497–501.

    PubMed  Article  Google Scholar 

  42. 42.

    Bamps M, Dok R, Nuyts S. Low-Level Laser Therapy Stimulates Proliferation in Head and Neck Squamous Cell Carcinoma Cells. Front Oncol. 2018;8:343.

    PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Cronshaw M, Parker S, Anagnostaki E, Mylona V, Lynch E, Grootveld M. Photobiomodulation and oral mucositis: a systematic review. Dentistry Journal. 2020;8:87.

    PubMed Central  Article  PubMed  Google Scholar 

  44. 44.

    Crous A, Abrahamse H. Low-intensity laser irradiation at 636 nm induces increased viability and proliferation in isolated lung cancer stem cells. Photomed Laser Surg. 2015;34:525–32.

    PubMed  Article  Google Scholar 

  45. 45.

    Pinheiro ALB, Carneiro NS, Vieira ALB, Brugnera A, Zanin FA, Barros RA, et al. Effects of low-level laser therapy on malignant cells: in vitro study. J Clin Laser Med Surg. 2002;20:23–6.

    PubMed  Article  Google Scholar 

  46. 46.

    Safety evaluation of low level light therapy on cancer cells—ProQuest. https://search.proquest.com/openview/1afa08a242f5168b00e2a7d009e64802/1?pq-origsite=gscholar&cbl=18750&diss=y. Accessed 6 Feb 2018.

  47. 47.

    Myakishev-Rempel M, Stadler I, Brondon P, Axe DR, Friedman M, Nardia FB, et al. A Preliminary Study of the Safety of Red Light Phototherapy of Tissues Harboring Cancer. Photomed Laser Surg. 2012;30:551–8.

    PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Wu S, Zhou F, Wei Y, Chen WR, Chen Q, Xing D. Cancer phototherapy via selective photoinactivation of respiratory chain oxidase to trigger a fatal superoxide anion burst. Antioxid Redox Signal. 2014;20:733–46.

    PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Frigo L, Luppi JSS, Favero GM, Maria DA, Penna SC, Bjordal JM, et al. The effect of low-level laser irradiation (In-Ga-Al-AsP - 660 nm) on melanoma in vitro and in vivo. BMC Cancer. 2009;9:404.

    PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Miss Sandrine Sotton for English editing services

Funding

Not applicable.

Author information

Affiliations

Authors

Contributions

Guarantor of integrity of the entire study EC; WB; JG; NM. study concepts and design N/A. literature research EC; WB. 4 clinical studies N/A. experimental studies/data analysis. statistical analysis N/A. manuscript preparation EC; WB; NM; JB; SL; RB; CR. manuscript editing EC; WB; JB; SL; RB; CR; NM. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Wafa Bouleftour.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

No conflict to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Courtois, E., Bouleftour, W., Guy, JB. et al. Mechanisms of PhotoBioModulation (PBM) focused on oral mucositis prevention and treatment: a scoping review. BMC Oral Health 21, 220 (2021). https://doi.org/10.1186/s12903-021-01574-4

Download citation

Keywords

  • Oral mucositis
  • Phototherapy
  • Photobiomodulation
  • Prevention